Drugs / 17β-E2
17β-E2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07010146 | Oct 2025 → Dec 2029 expected | bone remodeling disease, functional hypothalamic amenorrhea | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 17β-E2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07010146 ↗ |
| Known as | 17-beta estradiol | “natural form of estrogen (17-beta estradiol) given as a patch” NCT07010146 ↗ |
| Known as | 17β-estradiol | “transdermal physiologic 17β-estradiol replacement (17β-E2)” NCT07010146 ↗ |